{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,10]],"date-time":"2026-05-10T08:16:30Z","timestamp":1778400990782,"version":"3.51.4"},"reference-count":38,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,10,16]],"date-time":"2024-10-16T00:00:00Z","timestamp":1729036800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Therapies"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1016\/j.therap.2024.07.001","type":"journal-article","created":{"date-parts":[[2024,7,11]],"date-time":"2024-07-11T21:45:26Z","timestamp":1720734326000},"page":"623-633","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Physicians, pharmacists and take-home naloxone: What practices? The SINFONI study"],"prefix":"10.1016","volume":"79","author":[{"given":"M\u00e9lanie","family":"Duval","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2755-6490","authenticated-orcid":false,"given":"Aur\u00e9lie","family":"Aquizerate","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emmanuelle","family":"Jaulin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Morgane","family":"Rousselet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emmanuelle","family":"Kuhn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alain","family":"Guilleminot","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isabelle","family":"Nicolleau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Solen","family":"Pele","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Herault","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pascal","family":"Artarit","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eleni","family":"Soulidou-Jacques","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edouard-Jules","family":"Laforgue","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Caroline","family":"Victorri-Vigneau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.therap.2024.07.001_bib0195","unstructured":"World Health Organization. Opioid overdose. 2023. https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/opioid-overdose. [Accessed 5 July 2024]"},{"key":"10.1016\/j.therap.2024.07.001_bib0200","unstructured":"Agence nationale de s\u00e9curit\u00e9 du m\u00e9dicament et des produits de sant\u00e9 (ANSM). \u00c9tat des lieux de la consommation des antalgiques opio\u00efdes et leurs usages problematiques. 2019. https:\/\/ansm.sante.fr\/uploads\/2020\/10\/19\/20201019-rapport-antalgiques-opioides-fev-2019-3-pdf-2019-03-06.pdf. [Accessed 5 July 2024 (52 pp.)]"},{"issue":"2","key":"10.1016\/j.therap.2024.07.001_bib0205","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1111\/bcp.14415","article-title":"Ten-year trend of opioid and nonopioid analgesic use in the French adult population","volume":"87","author":"Daveluy","year":"2021","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.therap.2024.07.001_bib0210","doi-asserted-by":"crossref","first-page":"947006","DOI":"10.3389\/fphar.2022.947006","article-title":"Cross-sectional study of the prevalence of prescription opioids misuse in French patients with chronic non-cancer pain: an update with the French version of the POMI scale","volume":"13","author":"Kerckhove","year":"2022","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.therap.2024.07.001_bib0215","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1111\/add.16081","article-title":"The opioid epidemic: a worldwide exploratory study using the WHO pharmacovigilance database","volume":"118","author":"Robert","year":"2023","journal-title":"Addiction"},{"key":"10.1016\/j.therap.2024.07.001_bib0220","unstructured":"Code de la Sant\u00e9 Publique (CSP). Sous-section 4 : Centres d\u2019\u00e9valuation et d\u2019information sur la pharmacod\u00e9pendance et d\u2019addictovigilance (Articles R. 5132-112 \u00e0 R. 5132-116) : obligation de d\u00e9claration. 2012. https:\/\/www.legifrance.gouv.fr\/codes\/article_lc\/LEGIARTI000018043019\/2008-05-08. [Accessed 5 July 2024]"},{"key":"10.1016\/j.therap.2024.07.001_bib0225","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1097\/j.pain.0000000000002093","article-title":"Evolution of doctor shopping for oxycodone in the 67 million inhabitants in France as a proxy for potential misuse or abuse","volume":"162","author":"Soeiro","year":"2021","journal-title":"Pain"},{"key":"10.1016\/j.therap.2024.07.001_bib0230","first-page":"89","article-title":"Doctor shopping reveals geographical variations in opioid abuse","volume":"16","author":"Nordmann","year":"2013","journal-title":"Pain Physician"},{"key":"10.1016\/j.therap.2024.07.001_bib0235","doi-asserted-by":"crossref","first-page":"3789","DOI":"10.1111\/bcp.15323","article-title":"Increase of high-risk tramadol use and harmful consequences in France from 2013 to 2018: evidence from the triangulation of addictovigilance data","volume":"88","author":"Roussin","year":"2022","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.therap.2024.07.001_bib0240","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.puhe.2023.07.004","article-title":"Increase in hospitalisation-associated methadone intoxication in France following first COVID-19 lockdown","volume":"223","author":"Perino","year":"2023","journal-title":"Public Health"},{"key":"10.1016\/j.therap.2024.07.001_bib0245","doi-asserted-by":"crossref","first-page":"e2331398","DOI":"10.1001\/jamanetworkopen.2023.31398","article-title":"Trends in fatal poisoning among drug users in France From 2011 to 2021: an analysis of the DRAMES Register","volume":"6","author":"Revol","year":"2023","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.therap.2024.07.001_bib0250","unstructured":"Association fran\u00e7aise des centres d\u2019addictovigilance. D\u00e9c\u00e8s toxiques par antalgiques. 2020. https:\/\/addictovigilance.fr\/wp-content\/uploads\/2022\/11\/Resultats-DTA-2020.pdf.[Accessed 5 July 2024 (1 pp.)]"},{"key":"10.1016\/j.therap.2024.07.001_bib0255","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/j.therap.2018.07.001","article-title":"Int\u00e9r\u00eat de la mise \u00e0 disposition de la naloxone aupr\u00e8s des usagers de drogues pour le traitement d\u2019urgence de surdosage d\u2019opio\u00efdes","volume":"73","author":"Frauger","year":"2018","journal-title":"Therapies"},{"key":"10.1016\/j.therap.2024.07.001_bib0260","series-title":"Pr\u00e9venir et agir face aux surdoses d\u2019opio\u00efdes. Feuille de route 2019\u20132022","year":"2019"},{"key":"10.1016\/j.therap.2024.07.001_bib0265","unstructured":"Base de donn\u00e9es publiques de m\u00e9dicaments. SPC Prenoxad, France. 2018. https:\/\/base-donnees-publique.medicaments.gouv.fr\/extrait.php?specid=62968616. [Accessed 5 July 2024]"},{"key":"10.1016\/j.therap.2024.07.001_bib0270","unstructured":"Base de donn\u00e9es publique des m\u00e9dicaments. SPC Nyxoid, France. 2023. https:\/\/base-donnees-publique.medicaments.gouv.fr\/extrait.php?specid=63868145. [Accessed 5 July 2024]"},{"key":"10.1016\/j.therap.2024.07.001_bib0275","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.therap.2020.06.006","article-title":"Addictovigilance contribution during COVID-19 epidemic and lockdown in France","volume":"75","author":"Lapeyre-Mestre","year":"2020","journal-title":"Therapie"},{"key":"10.1016\/j.therap.2024.07.001_bib0280","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/j.therap.2023.03.008","article-title":"Pr\u00e9vention des surdoses opio\u00efdes et diffusion de naloxone (programme POP)\u00a0: r\u00e9sultats d\u2019un \u00e9tat des lieux r\u00e9alis\u00e9 aupr\u00e8s des structures d\u2019addictologie","volume":"78","author":"Mezaache","year":"2023","journal-title":"Therapie"},{"key":"10.1016\/j.therap.2024.07.001_bib0285","series-title":"Bon usage des m\u00e9dicaments opio\u00efdes\u202f: antalgie, pr\u00e9vention et prise en charge du trouble de l\u2019usage et des surdoses. Recommandations de bonne pratique","year":"2022"},{"key":"10.1016\/j.therap.2024.07.001_bib0290","unstructured":"Opinions et pratiques des m\u00e9decins g\u00e9n\u00e9ralistes lib\u00e9raux des Pays de la Loire. Opio\u00efdes : traitements de substitution, traitements antalgiques. 2021. https:\/\/www.orspaysdelaloire.com\/publications\/opinions-et-pratiques-des-medecins-generalistes-liberaux-des-pays-de-la-loire-opioides. [Accessed 5 july 2024]"},{"key":"10.1016\/j.therap.2024.07.001_bib0295","unstructured":"Cespharm, Conseil de l\u2019Ordre des pharmaciens. Document d\u2019information professionnelle : le pharmacien d\u2019officine acteur de la r\u00e9duction des risques et des dommages. 2023. https:\/\/www.ordre.pharmacien.fr\/les-communications\/focus-sur\/les-autres-publications\/le-pharmacien-d-officine-acteur-de-la-reduction-des-risques-et-des-dommages. [Accessed 5 July 2024]"},{"key":"10.1016\/j.therap.2024.07.001_bib0300","unstructured":"OFDT. Pratiques de prescription d\u2019antalgiques opio\u00efdes en m\u00e9decine g\u00e9n\u00e9rale. Tendances no 156, OFDT. 2023. https:\/\/www.ofdt.fr\/publications\/collections\/tendances\/pratiques-de-prescription-dantalgiques-opioides-en-medecine-generale-tendances-156-avril-2023\/. [Accessed 5 July 2024]"},{"key":"10.1016\/j.therap.2024.07.001_bib0305","unstructured":"Bouderbala B., Monge J., Reyne B. Diffusion de la naloxone en France, analyses et recommandations. 2019. https:\/\/www.addictaide.fr\/wp-content\/uploads\/2019\/09\/Diffusion-de-la-naloxone.pdf. [Accessed 5 July 2024 (12 pp.)]"},{"key":"10.1016\/j.therap.2024.07.001_bib0310","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/s12954-024-00941-y","article-title":"\u201cNaloxone? Not for me!\u201d First cross-assessment by patients and healthcare professionals of the risk of opioid overdose","volume":"21","author":"Aquizerate","year":"2024","journal-title":"Harm Reduct J"},{"key":"10.1016\/j.therap.2024.07.001_bib0315","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1111\/dar.12894","article-title":"Emergency department physicians\u2019 and pharmacists\u2019 perspectives on take-home naloxone: ED perspective on take-home naloxone","volume":"38","author":"Holland","year":"2019","journal-title":"Drug Alcohol Rev February"},{"key":"10.1016\/j.therap.2024.07.001_bib0320","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1111\/ajad.12982","article-title":"Physician and pharmacist: attitudes, facilitators, and barriers to prescribing naloxone for home rescue","volume":"29","author":"Martino","year":"2020","journal-title":"Am J Addict"},{"key":"10.1016\/j.therap.2024.07.001_bib0325","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1093\/ajhp\/zxaa387","article-title":"Preparing pharmacists to increase naloxone dispensing within community pharmacies under the Pennsylvania standing order","volume":"78","author":"Santa","year":"2021","journal-title":"Am J Health Syst Pharm"},{"key":"10.1016\/j.therap.2024.07.001_bib0330","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.drugpo.2019.09.008","article-title":"Barriers to naloxone use and acceptance among opioid users, first responders, and emergency department providers in New Hampshire, USA","volume":"74","author":"Bessen","year":"2019","journal-title":"Int J Drug Policy"},{"key":"10.1016\/j.therap.2024.07.001_bib0335","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1097\/01.j.pain.0000460357.01998.f1","article-title":"Rates of opioid misuse, abuse, and addiction in chronic pain: a systematic review and data synthesis","volume":"156","author":"Vowles","year":"2015","journal-title":"Pain"},{"key":"10.1016\/j.therap.2024.07.001_bib0340","doi-asserted-by":"crossref","first-page":"1911","DOI":"10.1111\/pme.12480","article-title":"Risk factors for serious prescription opioid-related toxicity or overdose among Veterans Health Administration patients","volume":"15","author":"Zedler","year":"2014","journal-title":"Pain Med"},{"key":"10.1016\/j.therap.2024.07.001_bib0345","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1213\/ANE.0000000000002496","article-title":"Risk factors for opioid-use disorder and overdose","volume":"125","author":"Webster","year":"2017","journal-title":"Anesth Analg"},{"key":"10.1016\/j.therap.2024.07.001_bib0350","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1017\/cem.2017.390","article-title":"Emergency physicians\u2019 attitudes and perceived barriers to the implementation of take-home naloxone programs in Canadian emergency departments","volume":"20","author":"Lacroix","year":"2018","journal-title":"CJEM"},{"key":"10.1016\/j.therap.2024.07.001_bib0355","doi-asserted-by":"crossref","first-page":"S154","DOI":"10.1016\/j.japh.2017.01.002","article-title":"Implementing an overdose education and naloxone distribution program in a health system","volume":"57","author":"Devries","year":"2017","journal-title":"J Am Pharm Assoc"},{"key":"10.1016\/j.therap.2024.07.001_bib0360","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1080\/08897077.2018.1439800","article-title":"An opioid overdose curriculum for medical residents: impact on naloxone prescribing, knowledge, and attitudes","volume":"39","author":"Taylor","year":"2018","journal-title":"Subst Abuse"},{"key":"10.1016\/j.therap.2024.07.001_bib0365","unstructured":"Legifrance. Code de la Sant\u00e9 publique. R\u00e9duction des risques. Article L. 3411-8 du Code de la Sant\u00e9 Publique. 2016. https:\/\/www.legifrance.gouv.fr\/codes\/article_lc\/LEGIARTI000031917375\/2016-01-28. [Accessed 5 July 2024]"},{"key":"10.1016\/j.therap.2024.07.001_bib0370","unstructured":"Haute autorit\u00e9 de sant\u00e9. Recommandation de bonne pratique \u00ab Contraception d\u2019urgence : dispensation en officine \u00bb. 2019. https:\/\/www.has-sante.fr\/jcms\/c_1759990\/fr\/contraception-d-urgence-dispensation-en-officine. [Accessed 5 July 2024]"},{"key":"10.1016\/j.therap.2024.07.001_bib0375","unstructured":"Legifrance. Journal officiel. D\u00e9cret no 2023-81 du 6 f\u00e9vrier 2023 relatif \u00e0 la participation des assur\u00e9s aux frais li\u00e9s \u00e0 la contraception d\u2019urgence et aux transports sanitaires. 2023. https:\/\/www.legifrance.gouv.fr\/jorf\/id\/JORFTEXT000047106646. [Accessed 5 July 2024]"},{"key":"10.1016\/j.therap.2024.07.001_bib0380","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/j.therap.2022.01.006","article-title":"Proportion and conditions of use of intranasal take-home naloxone kits: a retrospective study in two French outpatient addiction centers, 2016\u20132020","volume":"77","author":"Chappuy","year":"2022","journal-title":"Therapies"}],"container-title":["Therapies"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S004059572400074X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S004059572400074X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,11,23]],"date-time":"2024-11-23T13:55:16Z","timestamp":1732370116000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S004059572400074X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11]]},"references-count":38,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,11]]}},"alternative-id":["S004059572400074X"],"URL":"https:\/\/doi.org\/10.1016\/j.therap.2024.07.001","relation":{},"ISSN":["0040-5957"],"issn-type":[{"value":"0040-5957","type":"print"}],"subject":[],"published":{"date-parts":[[2024,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Physicians, pharmacists and take-home naloxone: What practices? The SINFONI study","name":"articletitle","label":"Article Title"},{"value":"Therapies","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.therap.2024.07.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Masson SAS on behalf of Soci\u00e9t\u00e9 fran\u00e7aise de pharmacologie et de th\u00e9rapeutique.","name":"copyright","label":"Copyright"}]}}